Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded at BidaskClub

BidaskClub upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a hold rating to a buy rating in a research note released on Thursday morning, BidAskClub reports.

Several other equities research analysts also recently commented on the company. TheStreet raised Amphastar Pharmaceuticals from a c rating to a b- rating in a report on Wednesday, August 7th. Wells Fargo & Co set a $29.00 price objective on Amphastar Pharmaceuticals and gave the company a buy rating in a report on Thursday, June 6th. Finally, Zacks Investment Research raised Amphastar Pharmaceuticals from a hold rating to a buy rating and set a $23.00 price objective for the company in a report on Wednesday, July 10th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $24.64.

NASDAQ:AMPH opened at $22.24 on Thursday. The company has a market cap of $1.07 billion, a P/E ratio of 52.47 and a beta of 1.35. The company has a quick ratio of 1.83, a current ratio of 2.81 and a debt-to-equity ratio of 0.13. Amphastar Pharmaceuticals has a twelve month low of $17.71 and a twelve month high of $25.43. The business has a 50 day moving average price of $20.40 and a two-hundred day moving average price of $21.31.



Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.03 by $0.05. The company had revenue of $79.00 million during the quarter, compared to the consensus estimate of $78.90 million. Amphastar Pharmaceuticals had a return on equity of 5.52% and a net margin of 16.33%. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.03 EPS. As a group, analysts anticipate that Amphastar Pharmaceuticals will post 0.15 earnings per share for the current fiscal year.

In other news, insider Jason B. Shandell sold 6,615 shares of the stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $20.31, for a total value of $134,350.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $20.78, for a total value of $207,800.00. Following the completion of the sale, the director now owns 49,309 shares in the company, valued at approximately $1,024,641.02. The disclosure for this sale can be found here. In the last three months, insiders sold 26,557 shares of company stock valued at $549,583. 30.80% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Martingale Asset Management L P raised its stake in Amphastar Pharmaceuticals by 8.2% in the 1st quarter. Martingale Asset Management L P now owns 220,438 shares of the company’s stock valued at $4,505,000 after acquiring an additional 16,692 shares during the period. BNP Paribas Arbitrage SA raised its stake in Amphastar Pharmaceuticals by 52,407.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,351 shares of the company’s stock valued at $150,000 after acquiring an additional 7,337 shares during the period. Sawtooth Solutions LLC bought a new stake in Amphastar Pharmaceuticals in the 1st quarter valued at $215,000. Two Sigma Advisers LP bought a new stake in Amphastar Pharmaceuticals in the 4th quarter valued at $275,000. Finally, Nordea Investment Management AB raised its stake in Amphastar Pharmaceuticals by 1.7% in the 1st quarter. Nordea Investment Management AB now owns 254,071 shares of the company’s stock valued at $5,192,000 after acquiring an additional 4,343 shares during the period. Institutional investors and hedge funds own 48.12% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Recommended Story: Operating Income

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.